At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MGTX Meiragtx Holdings Plc
Market Closed 05-17 16:00:00 EDT
5.71
+0.03
+0.53%
盘后5.71
+0.000.00%
16:02 EDT
High5.79
Low5.65
Vol68.72K
Open5.74
D1 Closing5.68
Amplitude2.45%
Mkt Cap367.19M
Tradable Cap147.37M
Total Shares64.31M
T/O392.42K
T/O Rate0.27%
Tradable Shares25.81M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Analyst Forecasts For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.